

Photocure ASA Results for 1st Quarter 2021

19 May 2021

Daniel Schneider, President and CEO

Erik Dahl, CFO



THE
BLADDER CANCER
COMPANY

Disclaimer



By reading this company presentation (the “Presentation”) or attending any meeting or oral presentation held in relation thereto, you (the “Recipient”) agree to be bound by the following terms, conditions and limitations.

The Presentation has been produced by Photocure ASA (the “Company”) for information purposes only and does not in itself constitute, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction. The distribution of this Presentation may be restricted by law in certain jurisdictions, and the Recipient should inform itself about, and observe, any such restriction. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction.

The Recipient acknowledges that it will be solely responsible for its own assessment of the Company, the market and the market position of the Company and that it will conduct its own analysis and be solely responsible for forming its own view of the potential future performance of the Company’s business. The Company shall not have any liability whatsoever (in negligence or otherwise) arising directly or indirectly from the use of this Presentation or its contents, including but not limited to any liability for errors, inaccuracies, omissions or misleading statements in this Presentation, or violation of distribution restrictions.

The Presentation will be used during an oral presentation and is therefore not a complete summary of the presentation held. Further, it is not the intention to provide, and the Recipient may not rely on the Presentation as providing, a complete or comprehensive analysis of the Company’s financial or trading position or prospects. Several factors could adversely affect the business, legal or financial position of the Company or the value of its securities. For a further description of other relevant risk factors, we refer to the Company’s annual report for 2020. Should one or more of these or other risks and uncertainties materialize, actual results may vary significantly from those described in this Presentation.

This Presentation contains certain forward-looking statements relating to inter alia the business, financial performance and results of the Company and the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts. Any forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources, are solely opinions and forecasts and are subject to risks, uncertainties and other factors that may cause actual results and events to be materially different from those expected or implied by the forward-looking statements. The Company cannot provide any assurance that the assumptions underlying such forward-looking statements are free from errors nor do any of them accept any responsibility for the future accuracy of opinions expressed in this Presentation or the actual occurrence of forecasted developments.

This Presentation speaks as at the date set out on herein. Neither the delivery of this Presentation nor any further discussions of the Company shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The Company does not assume any obligation to update or revise the Presentation or disclose any changes or revisions to the information contained in the Presentation (including in relation to forward-looking statements).

This Presentation is subject to Norwegian law, and any dispute arising in respect of this Presentation is subject to the exclusive jurisdiction of Norwegian courts.



First Quarter 2021 Highlights: Progress in both commercial regions despite Covid-19

+ 50%

Hexvix[®]/Cysview[®]
revenue growth

**EBITDA of
NOK 18
million**

**Two
Publications:**

World Journal of Urology:
Cost compare BLC vs. WLC
from claims data in Germany

BJUI: Meta-analysis of
benefits of PDD plus
chemotherapy
at TURBT

**Partnership
activity:**

Asieris: Licensed rights to
Hexvix in China

Canada: Guidelines
reinforced for Cysview

Genotests: Hexvix
MAA filed in Chile

COVID-19 Update

Access restrictions continue due to “third wave”

U.S.


- Significant access restrictions continued in Eastern states during Q1, access remains limited in certain areas (several waves of re-openings & closings)
- Large metropolitan cities beginning to loosen in Q2 (Los Angeles/New York City regions hardest hit during 2020 outbreak)
- New towers installed and placed into service during Q1, unit sales growth despite challenging environment

Europe

- Severe lockdowns and restrictions continued from Q4 2020 into Q1 2021
- Successful remote interactions in established markets, but difficulty in connecting with customers in re-launch markets
- Still in third wave of COVID-19 today: situation improving, expecting hospital access restrictions to lift over the summer

Hexvix/Cysview Revenue Development

Quarterly Reported Product Revenue by Segment (NOK '000)



Segment Trends


U.S. and Europe markets




Improving Trend in Both Regions Exiting Q1

First Quarter Hexvix/Cysview Units Last 3 Years by Month

U.S.



Europe





Q1 2021 Momentum in U.S.

- **12 new towers installed** in Q1 2021, **backlog suggests acceleration** in Q2 and throughout 2021
- **Unit volume up 4.2% in Q1** vs. prior year where Covid-19 surge occurred late March 2020
- Access restrictions are lifting in Q2 and **procedural volumes starting to pick up** across the United States
- **Contracting** led to first multi-hospital system agreement which included 5 rigid towers in 4 hospitals from a key health system in the Mid-Atlantic Region
- Momentum also being seen with contracting efforts to drive adoption and awareness of **surveillance opportunity** (flexible BLC)
- **Significant pick up in unit sales in March 2021** following challenging January and February


U.S.: Continued blue light cystoscope placements

Strong Start with 12 Installations in Q1 2021 Despite Access Restrictions



Annual New Installations

Tower Placement By Year




Q2 2020: 11 installations (8 Rigid & 3 Flex)
 Q3 2020: 7 installations (4 Rigid & 3 Flex)
 Q4 2020: 15 installations (10 Rigid & 5 Flex)
 Q1 2021: 12 installations (9 Rigid & 3 Flex)

*2012 – 17 of the 23 installations were converted clinical sites upon Cysview approval

Cumulative install base continues strong trend

Cumulative Tower Install



Key Initiatives Will Drive Growth for the U.S.



THE
BLADDER CANCER
COMPANY

CONTRACTING

Ongoing contracting with key health systems such as Kaiser and community-based Urology Groups

REFRESHED CYSVIEW CAMPAIGN

New campaign tailored to key physician segments & to educate on the disadvantage of using WLC alone

VETERANS AFFAIRS

Recent tower installations, pipeline building interest and demand with key VAs in the United States

PEER-TO-PEER

Virtual and on-site programs have increased given the surge of interest in Blue Light

PATIENT DEMAND

Cysview website locator map serving as a useful tool to get physicians to notice patients are looking for BLC locally

NON-PERSONAL PROMOTION

Expanding brand awareness, opening doors for sales reps through advertisements, mailers etc.



Q1 2021 Momentum in Europe

- **European business exceeded forecast** from original business plan
- Successfully re-connecting with leading **European KOL community** “as Photocure”
 - Introduced our commercial/medical team as the sponsor of Hexvix in priority markets
 - Very positive response to future cooperation with Photocure
- Established **cooperation projects with European capital equipment providers**
- **Completed work-down of excess inventory** in Germany from 2020 tax incentive
- **First signals of turn-around** in large growth markets (UK, FR, IT)

Large Untapped Potential in European Market

Established Hexvix Markets

Nordics: ~40% penetration

Active Hexvix Markets

DACH region: ~30% penetration

France: ~10% penetration

Benelux: ~10% penetration

Untapped Large EU Markets

UK, Italy, Spain, Poland

~0% penetration

Untapped Small EU Markets


Baltics, Czech Rep, Hungary,

Ireland, Greece, Portugal

~0% penetration

1. Globocan 2018 data on bladder cancer. Internal patient-based model supported by 3rd party sources
Potential = Total TURBTs in EU5 x Hexvix price

Photocure – Presentation of Q1 2021 Results



First Signals of Turn-Around in Large European Future Growth Markets



Q1 2021 Financials

Segment Performance First Quarter 2021

U.S. Segment

<i>Amounts in NOK million</i>	Q1 '21	Q1 '20	Change
Total revenues	27.3	28.2	-3%
Gross profit	26.6	26.7	- %
<i>% of revenue</i>	98%	95%	
Direct costs	-30.2	-34.9	-14%
Contribution (2)	-3.6	-8.2	
<i>% of revenue</i>	-13%	-29%	

- Revenue growth in USD: 8% (FX impact -10%)
- Volume increase 4% YoY
- Direct cost driven by cost containment and FX
- Covid-19 impact

Europe Segment

<i>Amounts in NOK million</i>	Q1 '21	Q1 '20	Change
Total revenues (1)	54.3	26.2	107%
Gross profit	50.0	21.9	128%
<i>% of revenue</i>	92%	84%	
Direct costs	-16.1	-3.9	
Contribution (2)	33.8	18.0	88%
<i>% of revenue</i>	62%	69%	

- FX impact:-2%
- Volume decline 9% YoY
- Staffing w/ additional FTEs as Covid-19 resolves
- Covid-19 impact

Consolidated Income Statement

First Quarter 2021

<i>Amounts in NOK million</i>	Q1 '21	Q1 '20	Change	FY '20
Hexvix®/Cysview® Revenue	81.6	54.4	50%	255.2
Other Revenue	6.6	0.6		1.3
Total Revenue	88.2	55.0	60%	256.5
Gross Profit	83.1	48.8	70%	238.0
Operating Expenses	-65.0	-53.6	21%	-241.9
EBITDA before Restructuring	18.1	-4.8		-3.9
Depreciation & Amort.	-5.9	-3.9		-19.3
EBIT before Restructuring	12.3	-8.6		-23.2
Restructuring Expenses	-	-1.9		-12.9
Net Financial Items	8.1	5.7		2.8
Earnings before Tax	20.3	-4.8		-33.2
Tax Expenses	-5.2	-12.9		10.8
Net earnings	15.2	-17.7		-22.4

Revenue

- Revenue driven by inclusion of European operations
 - Foreign exchange impact: USD down 10%
 - Sign-on fee from Asieris of NOK 6.4 million (Hexvix)

Operating Expenses

- Q1 increased due to investment in the European commercial operation
 - Operating expenses excluding European operation level with Q1 '20

EBITDA

- EBITDA improved NOK 22.9 million YoY
 - Driven by Asieris milestone (NOK 6.4 million), improved contribution Europe (NOK 15.8 million)

Net financial items

- Driven by interest component of Ipsen earnout and currency gain on earnout liability (Note 6 to accounts)

Cash Flow & Balance Sheet

First quarter 2021

<i>Amounts in NOK million</i>	Q1 '21	Q1 '20	FY '20
Operations Cash Flow	-8.2	3.0	15.6
Earnings before tax	20.3	-4.8	-33.2
Currency gain, unrealized	-14.0	-0.6	0.8
Contract receivable	-	12.3	23.0
Working capital	-20.5	-6.6	-5.9
Other	6.0	2.7	30.9
Investments Cash Flow	-0.3	-0.4	-166.2
Financing Cash Flow	3.0	-0.4	360.2
Net Change in Cash	-5.5	2.3	209.6

<i>Amounts in NOK million</i>	31.03.21	31.03.20	31.12.20
Non-current assets	353.9	54.6	363.8
Inventory & receivables	83.6	57.8	77.4
Cash & short-term deposits	329.4	127.6	334.9
Equity	530.0	190.4	508.1
Long-term liabilities	165.0	9.8	188.1
Current liabilities	71.8	39.8	79.8
Total balance	766.9	239.9	776.0

Cash Flow

- Comparison with Q1 '20 mainly driven by improved EBITDA from the European operation and from Asieris milestone payment (Hexvix), offset by one-off items
 - Q1 '20: Payment of contract receivable by Asieris
 - Q1 '21: Cash outflow from working capital, driven by European integration, accounts payable and receivables
- Net cash flow NOK -5.5 million, cash balance end of first quarter 2021 NOK 329.4 million

Assets

- Non-current assets includes intangibles and goodwill from Ipsen transaction totaling NOK 302.4 million


Liabilities

- Long-term liabilities includes deferred Ipsen earnout (NOK 126.9 million) and long-term portion of bank term loan (NOK 31.3 million)

Strategy for Shareholder Value Creation

Hexvix[®] /Cysview[®] – ambition to become standard of care in a \$1.9 billion total addressable market**

POSITION IN THE LIFE CYCLE



KEY SUCCESS FACTORS

APPROVAL > SURGICAL & SURVEILLANCE

ACCEPTANCE > MAJOR & LOCAL GUIDELINES*

ACCESS > PERMANENT AND FAVORABLE REIMBURSEMENT

"ACTIVATED" AWARENESS > PATIENT DEMAND VIA ADVOCACY GROUPS AND MEDIA

ACCELERATE > COMMERCIAL INVESTMENT TO OPTIMIZE THE OPPORTUNITY

*AUA, EAU, SUO, AFU, NICE, DGU guidelines

**TAM = estimation of total addressable market U.S. and EU5

†Source: Photocure internal patient-based model built on Globocan 2019 EU5 data.

Our Mission: Delivering transformative solutions to improve the lives of bladder cancer patients



THE
BLADDER CANCER
COMPANY

Photocure's four step strategy to deliver on our mission & vision



Photocure's global commercial bladder cancer platform will be the foundation for transformative deals and value growth

Anticipated Milestones & Corporate Priorities

- Regain prior sales momentum once Covid-19 is in significant decline
- Continue geographic expansion by penetrating untapped European markets, and through additional Hexvix licensing agreements ROW
- Further execute on contracting with Group Purchasing Organizations and Key Hospital/Health Systems in the U.S.
- Present/publish additional clinical data on the use of BLC with Hexvix/Cysview at medical conferences and in journals
- Report on progress of partnered companies and projects -- including Asieris agreements: Hexvix in China & Chile, Cevira Phase III development
- Continue evaluating strategic product or business opportunities

Summary



Summary

Continuing to execute; positioned for growth

- Managed well through a challenging quarter
- Achieved Hexvix/Cysview sales growth in Q1 2021, despite Covid-19 & foreign currency headwinds
- Added 12 new towers in Q1; run-rate above 2020 and current backlog suggests acceleration in 2021
- Continued to drive key initiatives in both commercial regions and with licensing partners
- Delivered positive EBITDA in Q1; Cash position NOK 329.4M vs. NOK 127.6M in Q1 2020
- Covid-19 volatility remains; guidance to be issued when trends are more clear
- Photocure is well-positioned for strong growth post-pandemic

Leading change in bladder cancer

Q&A